INDIA HEAD & NECK CANCER THERAPEUTICS MARKET FORECAST 2023-2030

According to a 2022 study titled ‘A study of head and neck cancer patients with reference to tobacco use, gender and subsite distribution’ published in the South Asian Journal of Cancer, head and neck squamous cell carcinoma (HNSCC) encompasses tumors in the oropharynx, nasopharynx, hypopharynx, oral cavity, and larynx. Asia accounts for a significant 57.5% of all head and neck cancers (HNCs) worldwide, with India alone contributing to 30% of all cancer cases. The Foundation for Head and Neck Oncology reports approximately 200,000 HNC cases in India annually, with oral cancer representing around 40% of these cases. Moreover, the northern and northeastern regions of the country bear a higher burden due to increased tobacco product consumption, limited awareness, and lower literacy rates.

Given the substantial number and diverse nature of HNC cases in India, the country has the potential to become a hub for clinical protocols and awareness campaigns. These initiatives would alleviate the burden of the disease and stimulate economic growth in this rapidly developing nation. Furthermore, ongoing medical research and technological advancements are leading to the development of novel and improved treatments for head and neck cancer. India has also seen remarkable progress in its healthcare infrastructure, with the establishment of specialized cancer centers, radiation treatment facilities, and multidisciplinary cancer care teams. These advancements have improved access to high-quality treatment options for patients with head and neck cancer. As a result, such factors are set to contribute to the growth of the India head & neck cancer therapeutics market during the forecast period.

The India head & neck cancer therapeutics market is segmented into therapeutic class, treatment type, route of administration, and end-user. The end-user segment includes hospitals, specialty clinics, ambulatory surgical centers, and other end-users. Specialty clinics are dedicated to providing comprehensive care for patients with head and neck cancer. These facilities house highly skilled healthcare specialists with extensive expertise in treating these specific cancers. Their specialized training and abilities contribute to improved patient outcomes and expanded treatment options. 

Conversely, hospitals play a vital role in providing comprehensive care to patients with head and neck cancer. They are responsible for accurate diagnosis, selecting the most appropriate treatment approaches, and delivering necessary therapies. In addition, hospitals and their medical staff remain at the forefront of therapeutic advancements for this cancer type, actively monitoring developments and exploring novel treatment options such as medications, immunotherapies, targeted therapies, and radiation therapies. 

Eminent companies operating in the India head & neck cancer therapeutics market include Amgen Inc, Sun Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, etc.

Sun Pharmaceutical Industries Ltd, headquartered in India, is a specialist pharmaceutical firm that offers a range of pharmaceutical formulations, including generic medications as well as branded generics. The company’s portfolio includes pharmaceutical products used for the treatment of neurological, nephrological, mental, gastroenterological, ophthalmologic, and orthopedic diseases and disorders, in addition to heart conditions.